SAN DIEGO, November 10, 2021 – ProSciento, Inc., a specialty clinical research organization (CRO) focused exclusively on metabolic diseases, today announced the appointment of Lynn Rudolph as Vice President of Human Resources. Ms. Rudolph joins ProSciento with an extensive track record of leading global team development, management, and retention programs for companies in accelerated growth phases.
“Our team, culture and corporate values are at the very foundation of what makes ProSciento successful and able to do the work we do to make a difference in the lives of patients with metabolic diseases. We’re thrilled to have Lynn in this key leadership role at a time of exciting growth and expansion of offices and services in the US and internationally, and as we continue to strengthen programs and strategies to attract new talent and support the continued growth and development of our leaders and teams,” commented Dr. Marcus Hompesch, ProSciento’s Chairman and Chief Executive Officer.
Ms. Rudolph’s career in human resources spans more than 20 years, including management of global human resource operations in highly regulated industries. Her background also includes implementing executive coaching and leadership development programs for individuals and teams. Prior to joining ProSciento, Ms. Rudolph served as the Senior Vice President of Human Resources at RW Baird, where she helped the company build its global talent strategy through innovative career and talent development programs. Before her role at RW Baird, she was Principal at Rudolph Coaching, a boutique executive coaching firm focused on delivering career development programs for emerging leaders in diverse industries. Prior to Rudolph Coaching, she was Vice President of Human Resources at PIMCO, a global asset management company with over $2 trillion of assets under management.
Ms. Rudolph earned her BS in Psychology from Northwestern University and was awarded Columbia University’s Coaching Certification. She is also a Hogan Assessments credentialed coach.
About ProSciento, Inc.
ProSciento is the leading specialized clinical research organization (CRO) focused on NASH, diabetes, obesity, and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 325 clinical studies for diabetes, NASH, and obesity, and has contributed to the development of numerous approved metabolic drugs and devices on the global marketplace. For more information, please visit www.nashpass.wpengine.com.
For business development inquiries, please contact:
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.